In a Rat Model of Acute Liver Failure, Icaritin Improved the Therapeutic Effect of Mesenchymal Stem Cells by Activation of the Hepatocyte Growth Factor/c-Met Pathway

<p>ICT decreases MSCs apoptosis via the HGF/c-Met pathway. (a) HGF levels for MSCs cultured with increasing concentrations of ICT as judged by ELISA. (b) Effect of ICT on MSCs of the c-Met receptor in vitro. Left: western blot for levels of c-Met. GAPDH served as a positive control. Right: mRNA levels of c-Met with various treatments. <sup>∗</sup>P &lt; 0.05 vs. control group. (c) Apoptosis was examined by Annexin V-FITC/PI staining and flow cytometric analysis. (d) Western blot analysis of cleaved caspase 3, Bax, and Bcl-2 levels. (e) mRNA expression levels of caspase-3, Bcl-2, and Bax in MSCs by qRT-PCR. <sup>∗</sup>P &lt; 0.05 vs. control group;<sup> #</sup>P &lt; 0.05 vs. ICT group. Each experiment was replicated 3 times.</p>

Evidence-Based Complementary and Alternative Medicine

fig5

Figure 5

Figure 5: In a Rat Model of Acute Liver Failure, Icaritin Improved the Therapeutic Effect of Mesenchymal Stem Cells by Activation of the Hepatocyte Growth Factor/c-Met Pathway 

Figure 5 | In a Rat Model of Acute Liver Failure, Icaritin Improved the Therapeutic Effect of Mesenchymal Stem Cells by Activation of the Hepatocyte Growth Factor/c-Met Pathway 